清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).

医学 肾细胞癌 T细胞受体 人类白细胞抗原 肿瘤科 癌症研究 内科学 细胞 T细胞 病理 免疫学 免疫系统 抗原 生物 遗传学
作者
Rosa Nadal,Stefan Barisic,Gina Scurti,Elena Cherkasova,Guolin Chen,Katherine Wood,Steven L. Highfill,Brian Wells,Georg Aue,Reem Shalabi,Thomas E. Hughes,Xin Tian,Yifei Xu,Ashkan A. Malayeri,Robert Reger,Michael I. Nishimura,Richard W. Childs
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:42 (4_suppl): 435-435
标识
DOI:10.1200/jco.2024.42.4_suppl.435
摘要

435 Background: Human endogenous retrovirus type E (HERV-E) is specifically expressed in ccRCC providing a safe target for T cell-based therapies. We investigated T cells transduced with a TCR targeting HERV-E (HERV-E T cells) for the treatment of mccRCC. Methods: This first-in-human study assessed the safety & efficacy of escalating doses of HERV-E T cells and manufacturing/clinical endpoints correlative analysis. HLA-A*11+ mccRCC patients (pts) were treated with a conditioning regimen, infusion of HERV-E T cells & IL-2. (NCT03354390). Results: Nineteen of185 pts tested were found to express HLA-A*11. 17 HLA-A*11 + pts enrolled on the study: 3 pts on each DL1-3 & 6 pts on DL4. 2 pts did not receive HERV-E T cells given disease progression during manufacturing period. Median age was 57 years. 86% received ≥ 3 prior systemic treatment (range 1-8). The manufacturing failure rate after first apheresis was 12% (n=2); both met target dose after second apheresis and repeat in vitro expansion. All HERV-E T cell products met release criteria for infusion including INF-γ production in response to HERV-E/HLA-A11-expressing tumor cells. Median HERV-E vector copy number (VCN) was 1.9. No dose-limiting toxicities (DLT), off-target toxicities or treatment-related deaths occurred. Pt#17 is on DLT monitoring period. 7 pts completed the planned 14 doses of IL-2 and all received at least 8 doses. Reasons for IL-2 discontinuation: hemodynamic (57%), cardiovascular (28%), pulmonary (28%), renal (14%) criteria & pts decision (14%). The best response was partial response in 7% & stable disease at least 8 weeks in 29% pts. HERV-E mRNA expression was detected in 5 primary & 9 metastatic specimens. HERV-E T cells were measurable in circulation post-dosing, with peak concentrations in the peripheral blood mononuclear compartment on day(D)+7. [DL1: 0.3 %, DL2: 1.2%, DL3: 0.5%, DL4: 12.3%]. Median HERV-E T cell VCN showed no correlation with HERV-E T cells peak concentration on D+4 & D+7. Conclusions: Proof of concept that HERV-T cells can induce tumor regression without evidence of causing off-target toxicities has been established by this trial. Infused HERV-E T cells were detectable transiently in vivo and induce effector cytokine production. Our initial results support the further development of HERV-E-directed therapies that focus on methods to improve in vivo persistence of TCR engineered T-cells and to target HERV-E antigens expressed on more commonly expressed HLA alleles.[Table: see text]
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_LN32Mn完成签到,获得积分10
2秒前
静_完成签到 ,获得积分10
8秒前
盛事不朽完成签到 ,获得积分10
23秒前
玩命的寄翠完成签到 ,获得积分10
26秒前
首席医官完成签到,获得积分10
42秒前
在水一方完成签到 ,获得积分0
45秒前
乌日完成签到 ,获得积分10
45秒前
50秒前
酷炫越泽发布了新的文献求助10
53秒前
隐形曼青应助ww采纳,获得10
54秒前
糊涂的青烟完成签到 ,获得积分10
57秒前
乐正怡完成签到 ,获得积分0
1分钟前
ww完成签到,获得积分10
1分钟前
666完成签到 ,获得积分10
1分钟前
xzl完成签到 ,获得积分10
2分钟前
tx完成签到,获得积分10
2分钟前
路在脚下完成签到 ,获得积分10
2分钟前
不爱吃西葫芦完成签到 ,获得积分10
2分钟前
天天快乐应助橙100采纳,获得10
2分钟前
vikey完成签到 ,获得积分10
2分钟前
不回首完成签到 ,获得积分10
2分钟前
简洁完成签到 ,获得积分10
2分钟前
萧子完成签到 ,获得积分10
2分钟前
不打扰完成签到 ,获得积分10
2分钟前
ycd完成签到,获得积分10
3分钟前
古炮完成签到 ,获得积分10
3分钟前
白桃完成签到 ,获得积分10
3分钟前
3分钟前
科研通AI2S应助科研通管家采纳,获得30
3分钟前
3分钟前
橙100发布了新的文献求助10
3分钟前
cadcae完成签到,获得积分10
3分钟前
沧海一粟米完成签到 ,获得积分10
3分钟前
chichenglin完成签到 ,获得积分10
4分钟前
宋芽芽u完成签到 ,获得积分10
4分钟前
荔枝小妹完成签到 ,获得积分10
4分钟前
领导范儿应助执着易形采纳,获得30
4分钟前
拼搏山槐完成签到 ,获得积分10
4分钟前
光亮秋天完成签到 ,获得积分10
4分钟前
称心的海蓝完成签到 ,获得积分10
4分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546022
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600229
捐赠科研通 1896383
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557